Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
Rhea-AI Summary
Tenaya Therapeutics (NASDAQ:TNYA) will report new interim data from Cohorts 1 and 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026.
Management will host a webcast at 8:00 a.m. ET, accessible via the Investors section under “Events & Presentations,” with an archived replay available for about 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – TNYA
In the Jun 3 session, TNYA declined 0.53%, reflecting a mild negative market reaction. Argus tracked a trough of -13.3% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 29 | Conference participation | Neutral | +8.8% | Announcement of participation and webcast access for Jefferies healthcare conference. |
| May 15 | Clinical data update | Positive | -8.3% | Positive interim TN-401 data showing reduced arrhythmia burden and EMA PRIME status. |
| May 06 | Earnings and pipeline | Positive | +7.4% | Q1 2026 results, cash runway into 2H 2027, and upcoming TN-201/TN-401 readouts. |
| Apr 27 | Clinical presentation | Positive | +4.1% | ASGCT late-breaking TN-401 data presentation and planned company webcast review. |
| Mar 11 | Earnings and funding | Positive | +4.0% | Q4/FY 2025 results, TN-201/TN-401 early readouts, and December equity raise proceeds. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent catalysts with positive or strategic tone often saw positive 24h moves, though one positive clinical readout drew a negative reaction, indicating occasional divergence on trial data.
Over the last few months, Tenaya highlighted several milestones, including Q4 2025 and Q1 2026 updates with cash of $80.9M and funding expected into the second half of 2027, aided by a $10.0M Alnylam upfront and potential milestones up to $1.1B. Clinical news for TN-401 in ARVC, including positive interim data and an ASGCT late-breaking oral presentation, produced mixed stock reactions. A recent conference appearance and earnings updates were followed by gains, framing today’s TN-201 interim data timing as another clinical waypoint within an active catalyst cycle.
Key Terms
phase 1b/2 medical
gene therapy medical
hypertrophic cardiomyopathy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to host webcast on Wednesday, June 3 at 8:00 a.m. ET
SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will report new interim data from Cohort 1 and Cohort 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026.
Webcast Details:
Tenaya Therapeutics will host a live webcast to review the new data from MyPEAK™-1 on Wednesday, June 3, 2026 at 8:00 a.m. ET. To access the live event, participants may register here. The live webcast will be available under “Events & Presentations” in the Investors section of Tenaya’s website.
An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the live event.
About MYBPC3-Associated Hypertrophic Cardiomyopathy (HCM)
Variants in the Myosin Binding Protein C3 (MYBPC3) gene are the most common genetic cause of hypertrophic cardiomyopathy (HCM), accounting for approximately
About TN-201
TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to address the underlying cause of MYBPC3-associated hypertrophic cardiomyopathy (HCM) by delivering a working MYBPC3 gene to heart muscle cells via a single intravenous infusion and thereby increasing insufficient MyBP-C protein levels with the aim of halting or even reversing disease after a single dose. The U.S. Food and Drug Administration has granted TN-201 Fast Track, Orphan Drug and Rare Pediatric Drug Designations. TN-201 has also received orphan medicinal product from the European Commission.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
